FeaturesChallenges and Opportunities in Pharmacogenomics Research  Recently, The Science Advisory Board questioned its members as to the challenges and barriers in pharmacogenomics research. This initiative was part of a solicitation from the National Institutes of Health and was intended to highlight the opportunities and to identify specific, achievable goals that will advance the field overall. The Science Advisory Board petitioned its members to provide insights that would help the National Institutes of Health identify pharmacogenomics research needs associated with discovery-based efforts, validation studies and applied research. This information will help lay the groundwork for accelerating the translation of pharmacogenomics knowledge into the clinical practice setting. The lack of consistent regulatory policies regarding pharmacogenomic tests threatens to undermine public confidence in this emerging field. Members of The Science Advisory Board believe that the National Institutes of Health has the objectivity to conduct studies that can standardize the implementation of pharmacogenomics. Establishing universal standards for analysis platform(s) and clinical validation criteria is a major roadblock to translating pharmacogenomics research to clinical practice. Recommendations presented in this report are designed to help establish the guidelines necessary for realizing the clinical applications of pharmacogenomics. A free copy of this mini report is available for download in PDF format here. ### << Previous [ View All Features ] |
|